Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Asymptomatic SARS-CoV-2 infection: Incidental findings on FDG PET/CT

Ricardo Bello Martinez, Munir Ghesani, Nasrin Ghesani and Somaii Gavane*

Division of Nuclear Medicine, Department of Radiology, Icahn School of Medicine at Mount Sinai; 1 Gustave L. Levy Pl, New York, NY 10029, United States

ABSTRACT

Rationale and Objectives: Identify the incidental findings of Covid-19 pneumonitis on 18F-FDG PET/CT scan in asymptomatic oncologic patients. The goal was to detect clinically unsuspected Covid-19 infections to prevent community spread.

Materials and Methods: Retrospective analysis was conducted to recognize the pattern of metabolic and radiographic alterations on 18F-FDG PET/CT scans in Covid-19 patients. 492 18F-FDG PET/CT scans were reviewed for pulmonary and systemic abnormalities.

Results: 18F-FDG PET/CT demonstrated new lung infiltrates in 29 asymptomatic patients. 13/29 patients had Covid-19 infection confirmed by nasopharyngeal nucleic acid PCR test. The most common lung abnormality was pure ground-glass opacity (GGO) (90%) in peripheral distribution (100%), involving 1 lobe in four patients (30.8%), 2–3 lobes in four patients, and 4-5 lobes in five patients (38.4%). Mean SUVmax was 4.7 (range 1.3–13.1). Ten patients developed symptoms, mainly fever, fatigue, and dry cough, within 6.4 ± 7.8 days (range 1–24). Of the available laboratory data of 12 patients, eight developed lymphopenia, and five patients had neutrophilia. Five patients required hospitalization, and two died of complications.

Conclusion: For a given geographic region in the later stage of a pandemic, such as Covid-19, community spread of the disease is common. Therefore, it is not surprising to find it in asymptomatic being imaged for other indications. Recognition of its manifestation and effectively mounting mitigation protocols is essential to further reduce SARS-CoV-2 spread, especially to susceptible groups, predominantly the elderly and people with comorbidities.

Keywords: Severe acute respiratory syndrome coronavirus 2; SARS-CoV-2; PET/CT; Covid-19

RÉSUMÉ

Justification et objectifs: Identifier les constats fortuits de la pneumonie à COVID-19 sur un scan TEP/TDM au 18F-FDG chez des patients oncologiques asymptomatiques. L’objectif était de détecter des infections à COVID-19 cliniquement insoupçonnées afin de prévenir la propagation dans la communauté.

Matériel et méthodologie: Une analyse rétrospective a été menée pour reconnaître le schéma des altérations métaboliques et radiographiques sur les scans TEP/TDM au 18F-FDG chez les patients atteints de la COVID-19. 492 scans TEP/TDM au 18F-FDG ont été examinés pour détecter des anomalies pulmonaires et systémiques.

Résultats: La TEP-TDM au 18F-FDG a mis en évidence de nouveaux infiltrats pulmonaires chez 29 patients asymptomatiques. Treize patients sur 29 présentaient une infection à Covid-19 confirmée par le test PCR de l’acide nucléique nasopharyngien. L’anomalie pulmonaire la plus courante était l’opacité en verre dépoli pure (90%) en distribution périphérique (100%), impliquant 1 lobe chez quatre patients (30.8%), 2 à 3 lobes chez quatre patients et 4 à 5 lobes chez cinq patients (38.4%). Le SUVmax moyen était de 4.7 (fourchette de 1,3 à 13,1). Dix patients ont développé des symptômes, principalement de la fièvre, de la fatigue et une toux sèche, en 6,4 ± 7,8 jours (fourchette de 1 à 24). Sur les données de laboratoire disponibles concernant 12 patients, huit ont développé une lymphopénie et cinq patients ont présenté une neutrophilie. Cinq patients ont dû être hospitalisés, et deux sont morts de complications.

Conclusion: Pour une région géographique donnée au stade avancé d’une pandémie, comme la COVID-19, la propagation communautaire de la maladie est courante. Par conséquent, il n’est pas surprenant de la trouver en mode asymptomatique en étant imagée pour d’autres indications. La reconnaissance de sa manifestation et la mise en place de protocoles d’atténuation efficaces sont essentielles pour réduire davantage la propagation du SRAS-CoV-2, en particulier dans les groupes sensibles, principalement les personnes âgées et les personnes présentant des comorbidités.
Introduction

The Covid-19 pandemic has drastically compromised many daily routines worldwide since December 2019. Over 49 million confirmed cases and more than 1,240,000 deaths have been reported worldwide [1]. The novel coronavirus SARS-CoV-2 was initially associated with a seafood market in China where live animals were sold [2]. Its transmission is primarily person to person, occurring in close contact mainly via respiratory droplets [3]. The virus uses the angiotensin-converting enzyme 2 (ACE2) as a cell receptor for cellular entry, mainly present in the human respiratory epithelium from where it can disseminate to other organs [4]; it can result in lung injury, and severe cases progress to severe respiratory distress syndrome or multi-organ failure [5].

Early-stage Covid-19 infection can be seen in chest CT as lung parenchymal ground-glass opacification (GGO) or consolidation that is likely to be bilateral and peripheral in distribution [6]. Asymptomatic or presymptomatic carriers contribute to the viral spread, and recognition of imaging findings suggestive of Covid-19 pneumonia plays a crucial role in detection and mitigation strategies, mainly when imaging is performed for SARS-CoV-2 unrelated reasons [7]. Elderly oncologic patients, who are susceptible to severe Covid-19 due to immunosuppression caused by anticancer treatment and malignancy, often have the absence of symptoms or are atypical, attributed to underlying conditions [8].

Imaging metabolic pathways with $^{18}$F-FDG PET/CT in oncologic applications aid accurate diagnosis, assessing disease status, and response to treatment on serial imaging [9]. Not infrequently, whole-body PET scans detect incidental like Covid-19 pneumonia characterized with a high degree of uptake [10]. $^{18}$F-FDG PET/CT plays a role in evaluating infectious and inflammatory diseases, monitoring disease progression and assessing treatment response, improving patient outcomes [11]. The discovery of new lung infiltrates on routine PET/CT suggestive of infection should raise suspicion, given the pandemic situation [12].

Despite public health plans to control the spread, the United States has more cases than any other country accounting for over 9 million confirmed cases [1]. As an international hub and its dense population, New York City became the pandemic’s epicenter in early 2020 [13]. We present Covid-19 infection FDG PET/CT findings in asymptomatic oncologic patients during the disease outbreak.

Material and methods

Retrospective analysis of PET/CT scan performed between March 10, 2020, and April 20, 2020, in a multicenter urban health system during the Covid-19 outbreak. Patients with unknown Covid-19 infection with incidental findings suggestive of infection were included. Clinical and demographics data were extracted from electronic medical records. Real-time polymerase chain reaction (RT-PCR) assays of the nasopharyngeal mucosa were used for microbiologic diagnosis. $^{18}$F-FDG PET/CT studies were performed on Biograph system, with an axial PET FOV of 25.6 cm, continuous bed motion 1.2 mm/s, 220 x 220 matrix, using PSF and TOF corrections, and reconstructed using OSEM with 2 iterations and 21 subsets (Siemens Healthcare); and on a Biograph mCT Flow PET/CT system, with an axial PET FOV of 21.6 cm, continuous bed motion 1.1 mm/s, 200 x 200 matrix, using PSF and TOF corrections and reconstructed using OSEM with 4 iteration and 5 subsets (Siemens Healthcare). Images were acquired after a fasting period of at least 6 hours, patients’ blood glucose levels were <200 mg/dL at the time of tracer injection with 4.6-4.8 MBq/Kg of $^{18}$F-FDG. Delta time was 50–65 min, the low mA, non-diagnostic CT images from PET/CT were used for attenuation correction and anatomic localization. The PET data were used to calculate the maximum SUV, a semi-quantitative parameter. A region of interest (ROI) was placed over abnormal lung parenchyma consolidations and mediastinal/hilar lymph nodes. The maximal activity in the ROI was calculated as the activity over lung consolidation/lymph node relative to the normal injected activity normalized by body weight. Imaging review was performed by a nuclear medicine physician at an Encore (version 6, MIM Software) workstation. The institutional Ethics Committee approved the study, and patients’ informed consent was waived (Figures 1–5).

Results

492 PET/CT scans were performed between March 10, 2020, and April 20, 2020. Twenty-nine asymptomatic patients had new lung infiltrates suspicious for an infectious/inflammatory process. 13/29 (45%) had Covid-19 infection that was diagnosed by RT-PCR subsequently. Patients’ clinical and PET characteristics are summarized in (Table 1). The mean age was 65.7 ± 10.7 years (range 49–79). Ten patients developed symptoms 6.4 ± 7.8 days (range 1–24) after PET/CT study. Mean time from PET/CT to positive RT-PCR was 15.6 ± 15.4 days (range 0–50). The most frequent symptoms were fever (70%), fatigue (70%), and dry cough (50%). Chills (30%), emesis (20%), myalgias (20%), altered mental status (20%), diarrhea (10%) and sore throat (10%) presented in lower proportions. Five patients required hospitalization, and two succumbed to complications.

Nine patients had only GGO, three patients had consolidation with GGO, and one patient had consolidative changes. Bilateral lung involvement was seen in nine patients. Four patients (30.8%) had 1 lobe affected, four patients had 2–3 lobes

---

**Abbreviations:** GGO, Ground-glass opacification; ACE2, Angiotensin-converting enzyme 2; RT-PCR, Real-time polymerase chain reaction.

All authors contributed to the conception or design of the work, the acquisition, analysis, or interpretation of the data. All authors were involved in drafting and commenting on the paper and have approved the final version.

**Funding:** This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Competing interests:** All authors declare no conflict of interest.

**Ethical approval:** The Institutional Ethics Committee approved the study, and patients’ informed consent was waived.

* Corresponding author.

**E-mail address:** somali.gavane@m entsinai.org (S. Gavane).
Figure 1. 70-year-old male with lung adenocarcinoma on alectinib presenting for routine PET/CT. (Panel A) MIP image shows hypermetabolic lesions in bilateral lungs (black arrows). Axial CT and fused PET images show multifocal bilateral hypermetabolic ground-glass opacities and consolidation (white arrows) consistent with Covid-19 pneumonia, as confirmed by RT-PCR. Hypermetabolic left lower lobe mass (red arrow) consistent with primary malignancy. (Panel B) PET/CT obtained two months after shows near-complete resolution of bilateral opacities with minimal residual GGO. Subpleural parenchymal bands can be seen in the right lower lobe and left fissure thickening (white arrows). Persistent hypermetabolic left lower lobe mass (red arrow).

Discussion

Lung infiltrates on PET/CT of cancer patients may be the first sign of SARS-CoV-2 infection but resulted in an alternative diagnosis due to negative RT-PCR test for SARS-CoV-2. The most common diagnostic test used for SARS-CoV-2 is the nasopharyngeal nucleic acid amplification test with high specificity but variable sensitivity to exclude infection [14]. It is essential to note the limitations of diagnostic test accuracy of the nasopharyngeal swab. First, it is unclear how different manufacturers assess their test performance under flexible regulations allowed by emergency use authorizations (EUA) of these tests granted by The Food and Drug Administration (FDA). The diagnostic test’s clinical sensitivity and specificity also vary by the specimen source, quality of sampling technique, disease course timing, and illness severity. Additionally, no robust data assessing involved, and five patients (38.4%) had 4–5 lobes. All patients had a peripheral distribution of opacities. The mean SUVmax of the opacities was 4.7 (range 1.3–13.1). FDG avid thoracic lymphadenopathy was seen in seven patients. Out of the 12 patients with labs available for review, eight patients developed lymphopenia (66.7%) and five neutrophilia (41.7%).
the nasopharyngeal test sensitivity on asymptomatic infected individuals exist. Given our cohort’s high pretest probability for having been located in a prevalent area, one needs a highly sensitive test to reliably deemed true-negatives; hence we might have underestimated our positive cases [15].

Nonetheless, testing allows tracking the viral spread and isolation of infected cases, estimates local prevalence, necessary in the risk-benefit assessment of safety of performing routine nonurgent radiologic care or postponing any examination given the risk of healthcare-acquired Covid-19, considering patients’ demographics and comorbidities [16]. RT-PCR is also used to triage before debilitating interventions like surgery or chemoradiation that can be complicated by a severe infectious process.

Many asymptomatic carriers lack radiographic abnormalities or have a false negative RT-PCR that undermines prevention measurements based on the presence of symptoms, imaging findings, or laboratory results [17]. It is essential to adapt universal prevention strategies as masking, physical distancing,
Figure 3. 56-year-old male with Hodgkin’s lymphoma presents for follow-up PET/CT complaining of neck discomfort. (Panel A) MIP image shows uptake in bilateral lungs and mediastinum and bilateral neck, right axilla, right pelvis, and inguinal regions (red arrows). Axial PET/CT shows bilateral ground-glass opacities in the upper lobes and patchy consolidations in the lower lobes (white arrows) with associated mediastinal lymphadenopathy (black arrows). (Panel B) PET/CT obtained four months after shows residual ground-glass opacities and resolution of mediastinal lymphadenopathy. MIP images show persistent cervical and right axillary, pelvic, and inguinal lymphadenopathy (red arrows) related to lymphoma.

Figure 4. 54-year-old female with breast cancer on chemotherapy presents for restaging PET/CT. MIP images demonstrate hypermetabolic foci in the lungs and mediastinum (black arrows). Axial PET/CT shows bilateral confluent ground-glass opacities (white arrows) and precarinal lymph node (black arrow).
Figure 5. 54-year-old male with lacrimaligneous melanoma on nivolumab. MIP image shows metastatic left lower lobe nodule and right scapula lesion with mediastinal lymphadenopathy (black arrows). Axial PET/CT shows bilateral upper lobes lung opacities with mild uptake (white arrows). RT-PCR done resulted negative.

Table 1
Demographic data, clinical and PET/CT findings.

| Sex | Age | Primary Cancer | Symptoms | Type of lung abnormality | № of Lobes Affected | Lung findings SUVmax | Outcome |
|-----|-----|----------------|----------|--------------------------|---------------------|----------------------|---------|
| F   | 67  | Lung           | Asymptomatic | GGO                      | 3                   | 4.8                  | Recovered |
| M   | 78  | Urothelial     | Fever, Emesis | GGO                      | 4                   | 1.3                  | Recovered |
| M   | 65  | DLBCL          | Fever, Cough | GGO                      | 1                   | 1.9                  | Recovered |
| M   | 79  | DLBCL, EBV     | Fever, AMS   | GGO                      | 3                   | 2.1                  | Recovered |
| F   | 67  | Hodgkin's Lymphoma | Fever | GGO                      | 2                   | 2.4                  | Deceased |
| F   | 76  | DLBCL          | Fever, Cough | Consolidation            | 1                   | 2.6                  | Recovered |
| M   | 64  | Multiple myeloma | Fever, Cough, Myalgia | GGO                      | 5                   | 1.7                  | Deceased |
| M   | 79  | Colon          | Fatigue, Emesis | GGO                      | 1                   | 1.6                  | Recovered |
| F   | 50  | Transformed DLBCL | Fatigue, Cough, Myalgia | GGO                      | 2                   | 7.9                  | Recovered |
| M   | 49  | HER2+ Esophageal adenocarcinoma | Asymptomatic | GGO with consolidation | 1                   | 7.1                  | Recovered |
| F   | 54  | Breast         | Asymptomatic | GGO                      | 5                   | 4.6                  | Recovered |
| M   | 70  | Lung           | Fever, Cough | GGO with consolidation | 5                   | 13.1                 | Recovered |

F = female; M = male; DLBCL = diffuse large B cell lymphoma; GGO = ground-glass opacity; AMS = altered mental status

and hand hygiene to prevent asymptomatic spread and exposure to vulnerable patients. Five of the presented cases were subsequently hospitalized, and two died, reflecting the vulnerability of elderly oncologic patients. In health care centers where exposure risks are higher, comprehensive measures as Covid-19 safety algorithms, readily available personal protective equipment, and protocols for staff and patients are the cornerstone for safe operations. Telehealth, as the remote delivery of care and tools for employees attesting their health status before each shift, should also be implemented when feasible [18,19].

The oncologic population commonly presents with benign infectious/inflammatory lung processes, often treatment-related, that nor radiographic or scintigraphy findings can differentiate from other viral or non-viral atypical types of pneumonia [20]. Imaging should be used as an adjunct to patient management [21]. FDG PET/CT is useful in assessing infectious and inflammatory cardiopulmonary processes. It allows quantification of radioactivity, providing a biomarker of the inflammatory process in vivo [22]. It is also sensitive for detecting lymph node involvement and assesses response to treatments; however, PET/CT scan currently does not have a role in the management of Covid-19. The long-time interval between PET/CT scan RT-PCR in our population can be explained by testing-supply shortage at that time.
References

[1] The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Coronavirus COVID-19 global cases. https://coronavirus.jhu.edu/map.html. Accessed Nov 2, 2020.

[2] World Health Organization. Novel coronavirus situation report -2. January 22, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200122-sitrep-2-2019-ncov.pdf.

[3] van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–1567.

[4] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;182(2):271-280.e278.

[5] Petrelli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.

[6] El Homsi M, Chung M, Bernheim A, et al. Review of chest CT manifestations of COVID-19 infection. Eur J Radiol Open. 2020;7.

[7] Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382(22):2081–2090.

[8] Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791.

[9] Fahim UI, Cook GJ. PET/CT in oncology. Clin Med. 2012;12(4):368–372.

[10] Johnson LN, Vesselle H. COVID-19 in an asymptomatic patient undergoing FDG PET/CT. Radiol Case Rep. 2020;15(10):1809–1812.

[11] Kung BT, Seraj SM, Zadeh MZ, et al. An update on the role of (18)F-FDG-PET/CT in major infectious and inflammatory diseases. Am J Nucl Med Mol Imaging. 2019;9(6):255–273.

[12] Zou S, Zhu X. FDG PET/CT of COVID-19. Radiology. 2020;296(2):E118.

[13] Gonzalez-Reiche AS, Hernandez MM, Sullivan MJ, et al. Introductions and early spread of SARS-CoV-2 in the New York City area. Science. 2020;369(6501):297–301.

[14] Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics in context. Sci Transl Med. 2020;12(546):eaax1931.

[15] Woloshin S, Patel N, Kesselheim AS. False negative tests for SARS-CoV-2 infection — challenges and implications. N Engl J Med. 2020;383(6):e38.

[16] Davenport MS, Bruno MA, Iyer RS, et al. ACR statement on safe resumption of routine radiology care during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Radiol. 2020;17(7):839–844.

[17] Inui S, Fujikawa A, Jitsu M, et al. Chest CT findings in cases from the cruise ship “Diamond Princess” with coronavirus disease 2019 (COVID-19). Radiology. 2020;296.

[18] West HJ. Teledermatology in oncology: delivering on an overdue promise in the COVID-19 era. Front Oncol. 2020;10:578888-578888.

[19] Grewal US, Terasuchi S, Baj HS, Telehealth and palliative care for patients with cancer: implications of the COVID-19 pandemic. JMIR Cancer. 2020;6(2) e20288-e20288.

[20] Raptis CA, Hammer MM, Short RG, et al. Chest CT and coronavirus disease (COVID-19): a critical review of the literature to date. AJR Am J Roentgenol. 2020;214(5):839–842.

[21] Rubin GD, Ryerson CJ, Haramati LB, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner society. Radiology. 2020;296(1):172-180.

[22] Capitanio S, Nordin AJ, Noraini AR, Rossetti C. PET/CT in nononcological lung diseases: current applications and future perspectives. Eur Respir Rev. 2016;25(141):247–258.